Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.

Online curriculum expands with advanced clinical cases in prostate cancer and neuroendocrine tumors including ...

UChicago researchers identify a previously unknown RNA molecule that allows prostate cancer cells to escape targeted ...

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...

Prostate cancer treatment has undergone a remarkable transformation over the past decade, with the integration of androgen ...

Researchers investigating a deadly cancer’s ability to evade treatment have discovered its secret weakness, paving the way ...

Perioperative apalutamide plus ADT and surgery lowered risk of recurrence or death by 62% in high-risk localized or locally advanced prostate cancer.

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting ...

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed ...

The vast majority of people diagnosed with prostate cancer can expect to live long, full lives thanks to improved screening that catches the disease in its early and most treatable stages. But ...

I f prostate cancer has spread to other areas of your body, your doctor may recommend androgen deprivation therapy (ADT), which halts the production of androgen hormones, especially testosterone.

Men diagnosed with incurable advanced prostate cancer 'are living longer' - ...